基于下一代RNA测序的嫌色细胞肾细胞癌及相关嗜酸细胞肿瘤的生物标志物特征
该研究对1049例肾细胞癌标本的RNA测序数据进行分析,鉴定出嫌色细胞肾细胞癌中相对富集的FOXI1、RHCG和LINC01187。在197例肾细胞癌组织切片中验证,所有原发和转移性经典型嫌色细胞肾细胞癌均均匀阳性表达这三种标志物,而其他亚型均无明确染色。
要点
- FOXI1、RHCG和LINC01187在经典型嫌色细胞肾细胞癌中原发和转移灶均均匀阳性。
- 其他亚型肾细胞癌均无明确染色,有助于鉴别诊断。
- 两例伴灶性表达及高尔基样RHCG染色的嗜酸性嫌色细胞肾细胞癌存在MTOR基因突变。
核心结论
- FOXI1、RHCG和LINC01187是嫌色细胞肾细胞癌的谱系特异性标志物,有助于准确分类和诊断。
研究设计与样本
- 对来自TCGA和内部研究的1049例肾细胞癌标本的RNA测序数据进行整合分析。
- 在197例肾细胞癌病例的全组织切片(包括原发和转移性肿瘤)中,用免疫组化评估FOXI1和RHCG蛋白,用RNA原位杂交评估LINC01187 mRNA。
主要发现
- 所有原发和转移性经典型嫌色细胞肾细胞癌均对FOXI1、RHCG蛋白和LINC01187转录本呈均匀阳性标记。
- 具有嗜酸细胞特征的不分类肾细胞癌、嗜酸细胞瘤和混合性嗜酸细胞肿瘤,以及除两例外的所有嗜酸性嫌色细胞肾细胞癌也呈阳性染色。
- 所有其他亚型的原发和转移性肾细胞癌均无FOXI1、RHCG或LINC01187的明确染色。
- 正常肾脏中,FOXI1、RHCG和LINC01187在远端肾单位,特别是闰细胞中检测到。
- 两例FOXI1和LINC01187灶性表达且RHCG呈高尔基样染色的嗜酸性嫌色细胞肾细胞癌,经DNA测序发现MTOR基因突变。
临床怎么用
- FOXI1、RHCG免疫组化和LINC01187 RNA原位杂交可用于确认嫌色细胞肾细胞癌的细胞起源并辅助准确分类诊断。
局限性
- 两例嗜酸性嫌色细胞肾细胞癌呈灶性FOXI1和LINC01187表达及高尔基样RHCG染色,且携带MTOR突变,提示少数病例染色模式不典型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal cell carcinomas (RCCs) are a heterogeneous group of neoplasms. Recent sequencing studies revealed various molecular features associated with histologic RCC subtypes, including chromophobe renal cell carcinoma (ChRCC). OBJECTIVE: To characterize the gene expression and biomarker signatures associated with ChRCC. DESIGN, SETTING, AND PARTICIPANTS: We performed integrative analysis on RNA sequencing data available from 1049 RCC specimens from The Cancer Genome Atlas and in-house studies. Our workflow identified genes relatively enriched in ChRCC, including Forkhead box I1 (FOXI1), Rh family C glycoprotein (RHCG), and LINC01187. We assessed the expression pattern of FOXI1 and RHCG protein by immunohistochemistry (IHC) and LINC01187 mRNA by RNA in situ hybridization (RNA-ISH) in whole tissue sections representing a cohort of 197 RCC cases, including both primary and metastatic tumors. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The FOXI1 and RHCG IHC staining, as well as the LINC01187 RNA-ISH staining, was evaluated in each case for intensity, pattern, and localization of expression. RESULTS AND LIMITATIONS: All primary and metastatic classic ChRCCs demonstrated homogeneous positive labeling for FOXI1, RHCG proteins, and LINC01187 transcript. Unclassified RCC with oncocytic features, oncocytoma, and hybrid oncocytic tumor, as well as all but two cases of eosinophilic ChRCC also stained positive. Importantly, metastatic and primary RCC of all other subtypes did not demonstrate any unequivocal staining for FOXI1, RHCG, or LINC01187. In normal kidney, FOXI1, RHCG, and LINC01187 were detected in the distal nephron segment, specifically in intercalated cells. Two cases of eosinophilic ChRCC with focal expression of FOXI1 and LINC01187, and Golgi-like RHCG staining were found to contain MTOR gene mutations upon DNA sequencing. CONCLUSIONS: We demonstrate a pipeline for the identification and validation of RCC subtype-specific biomarkers that can aid in the confirmation of cell of origin and may facilitate accurate classification and diagnosis of renal tumors. PATIENT SUMMARY: FOXI1, RHCG, and LINC01187 are lineage-specific signature genes for chromophobe renal cell carcinoma.
引用
- Skala SL, Wang X, Zhang Y, et al. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. Eur Urol. 2020. PMID: 32299640. doi:10.1016/j.eururo.2020.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。